COTA Adds Former Director of the National Cancer Institute and Commissioner of Food and Drug Administration to Board of Directors

NEW YORK, May 14, 2015 (GLOBE NEWSWIRE) -- COTA Inc. (Cancer Outcomes Tracking and Analysis) has added Dr. Andrew von Eschenbach, the former director of the National Cancer Institute and Commissioner of the U.S. Food and Drug Administration, to its Board of Directors.

"Our Nation is struggling to control the rising cost of cancer care and needs novel approaches to maintain affordable access to a growing list of life saving therapies. I am excited to contribute as a director to COTA. Through novel analytics and interactive software COTA is enabling the delivery of value based care aimed to maintain and improve clinical outcomes while eliminating unnecessary care and cost."

The cost of cancer care in the U.S. alone is expected to surge past $206 billion dollars by 2020. One of the major challenges in the industry is how to reduce the rising costs while still maintaining or increasing patient outcomes.

Dr. Andrew Pecora, COTA Founder and Executive Chairman said, "We are very pleased to have Dr. von Eschenbach join the COTA team and provide critical guidance for the road ahead. His vast experience in health care policy will help COTA lead the way in assisting oncologists to optimize cancer care and move a value-based care system forward."

About COTA, Inc.

Developed by world-leading oncologists COTA, Inc., has developed the unique CNA (COTA Nodal Address) System to precisely classify cancer patients into meaningful clinical and prognostic cohorts. Using this sorting technique, COTA is able to account for the biologic variances of cancer, thus permitting more in-depth analyses of treatment variances. This enables doctors and health plans to improve patient care and move from fee-for-service to value-based reimbursement models. COTA offers providers, patients and payers with the actionable, real-time insights needed to improve clinical outcomes, while reducing the costs. Based in New York City, the Company's mission is to enable optimal care for every cancer patient. To learn more about COTA, call (866) 648-3833 or visit

Hitman, Inc., has been named the agency of record for COTA, Inc.

CONTACT: Media Contact: Steve Brazell Hitman, Inc. (212) 300.6026 contractahit@yourhitman.comSource:COTA, Inc.